2009
High Expression of Mammalian Target of Rapamycin Is Associated with Better Outcome for Patients with Early Stage Lung Adenocarcinoma
Anagnostou VK, Bepler G, Syrigos KN, Tanoue L, Gettinger S, Homer RJ, Boffa D, Detterbeck F, Rimm DL. High Expression of Mammalian Target of Rapamycin Is Associated with Better Outcome for Patients with Early Stage Lung Adenocarcinoma. Clinical Cancer Research 2009, 15: 4157-4164. PMID: 19509151, DOI: 10.1158/1078-0432.ccr-09-0099.Peer-Reviewed Original ResearchConceptsLung cancer patientsMTOR expressionCancer patientsMammalian targetEarly-stage lung adenocarcinomaHigh mTOR expressionIndependent lower riskMedian overall survivalStage IA patientsProtein expressionSubgroup of patientsLung adenocarcinoma patientsStage lung adenocarcinomaMTOR protein expressionRole of mTOROverall survivalPathologic characteristicsPatient survivalValidation cohortAdenocarcinoma groupAdenocarcinoma patientsPrognostic stratificationLung cancerTraining cohortFavorable outcomeAssociation of expression of bcl-2 with outcome in non-small cell lung cancer
Anagnostou V, Lowery F, Syrigos K, Frangia K, Zolota V, Panagopoulos N, Dougenis D, Tanoue L, Detterbeck F, Homer R, Rimm D. Association of expression of bcl-2 with outcome in non-small cell lung cancer. Journal Of Clinical Oncology 2009, 27: e22039-e22039. DOI: 10.1200/jco.2009.27.15_suppl.e22039.Peer-Reviewed Original ResearchLung cancer patientsSquamous cell carcinomaBcl-2 expressionCancer patientsCell carcinomaBcl-2Non-small cell lung cancerYale-New Haven HospitalIndependent lower riskPatras University HospitalMedian overall survivalProtein expressionPotential prognostic parametersSubgroup of patientsCell lung cancerHigh Bcl-2 expressionNew Haven HospitalBcl-2 protein expressionAssociation of expressionBcl-2 protein levelsOverall survivalPatient survivalValidation cohortPathological characteristicsPrognostic parameters
2006
Evaluation and definitive management of medically inoperable early stage non-small-cell lung cancer. Part 2: newer treatment modalities.
Decker RH, Tanoue LT, Colasanto JM, Detterbeck FC, Wilson LD. Evaluation and definitive management of medically inoperable early stage non-small-cell lung cancer. Part 2: newer treatment modalities. Oncology 2006, 20: 899-905; discussion 905-8, 913. PMID: 16922260.Peer-Reviewed Original ResearchConceptsCell lung cancerLung cancerPoor baseline pulmonary functionCurative treatment alternativeInoperable early stageSingle-modality radiotherapyComorbid medical illnessesBaseline pulmonary functionBetter overall survivalMinority of patientsRadiotherapy dose escalationDefinitive treatment optionEarly-stage patientsOverall survival dataNew treatment modalitiesMediastinal nodalAdvanced diseaseCurative resectionDistant failureOverall survivalPulmonary functionDose escalationDefinitive managementMedical illnessCancer mortalityEvaluation and definitive management of medically inoperable early-stage non-small-cell lung cancer. Part 1: Assessment and conventional radiotherapy.
Decker RH, Tanoue LT, Colasanto JM, Detterbeck FC, Wilson LD. Evaluation and definitive management of medically inoperable early-stage non-small-cell lung cancer. Part 1: Assessment and conventional radiotherapy. Oncology 2006, 20: 727-36. PMID: 16841796.Peer-Reviewed Original ResearchConceptsCell lung cancerLung cancerPoor baseline pulmonary functionCurative treatment alternativeSingle-modality radiotherapyComorbid medical illnessesBaseline pulmonary functionBetter overall survivalEarly-stage patientsMinority of patientsRadiotherapy dose escalationDefinitive treatment optionOverall survival dataMediastinal nodalAdvanced diseaseCurative resectionDistant failureOverall survivalPulmonary functionDose escalationDefinitive managementMedical illnessCancer mortalityTreatment optionsRadiofrequency ablation